Heart Health
A Heart Drug Slashed a Genetic Risk Factor — but Didn’t Prevent Heart Attacks
Novartis and Ionis’s pelacarsen dramatically lowered lipoprotein(a), a common inherited cardiovascular risk, yet failed to cut heart attacks, strokes or cardiac deaths in its pivotal trial.